Update on Treatment and Prevention of Chronic Antibody Mediated Rejection in Renal Transplant Recipients

著者

  • Salman Tahir Shafi Sharif Medical and Dental College, Lahore

##doi.readerDisplayName##:

https://doi.org/10.53778/pjkd40353

キーワード:

Rejection, kidney transplant、 acute rejection、 chronic rejection、 antibody mediated rejection、 complement,、 plasmapheresis、 Bortezomib,、 Rituximab、 Eculizumab、 Tocilizumab

要旨

Chronic antibody mediated rejection (AMR) is a major cause of allograft failure1,2. Chronic AMR clinically presents with proteinuria and gradual decline in renal function. The underlying mechanisms of AMR include both antibody mediated complement-dependent cytotoxicity, complement-independent cellular cytotoxicity and other mechanisms. The purpose of this review is to appraise recent literature on diagnosis, treatment and prevention of chronic AMR.

PJKD

ダウンロード

発行日

2021-01-31

巻号

巻 4 号 03 (2020): Pakistan Journal of Kidney Diseases

セクション

Review Article

ライセンス

コピーライト (c) 2021 Salman Tahir Shafi

Creative Commons License

この資料のライセンスはCreative Commons 表示 - 非営利 4.0 国際 です。

引用方法

Update on Treatment and Prevention of Chronic Antibody Mediated Rejection in Renal Transplant Recipients. (2021). Pakistan Journal of Kidney Diseases, 4(03). https://doi.org/10.53778/pjkd40353